A Non-invasive, On-demand Eye Drop-based Gene Therapy For Neovascular Blindness
Project Title:
A Non-invasive, On-demand Eye Drop-based Gene Therapy For Neovascular Blindness
Chief Investigator:
Prof Liu Guei-Sheung
Co-Investigators:
Prof Bang V. Bui, A/Prof Luis Alarcon-Martinez, Dr David Cordeiro Sousa
Aim
This study aims to advance anti-VEGF therapy (soluble VEGF-binding protein) by developing a tunable gene therapy system that can be activated through topical eye drop administration, enabling patients to self-administer treatment in a minimally invasive, on-demand manner for the management of neovascular eye diseases.
Methods
The topical bioavailability of the small-molecule eye drop used to activate the tunable gene therapy system was first validated in the mouse retina using HPLC-mass spectrometry. The therapeutic efficacy of the tunable anti-VEGF gene therapy was subsequently evaluated in vivo using two complementary mouse models: the Kimba model, a clinically relevant model of the advanced stages of proliferative diabetic retinopathy, and the Akita model, a well-established model of spontaneous type 1 diabetes.
Conclusion
This study provides proof-of-concept evidence that a tunable anti-VEGF gene therapy system, activated through non-invasive topical administration of a small-molecule eye drop, represents a viable and promising therapeutic strategy for neovascular and diabetic eye diseases. These findings represent a meaningful advancement toward the development of a minimally invasive, patient-controlled gene therapy platform for the long-term management of neovascular eye diseases, warranting further investigation in larger preclinical models and future clinical translation.
Lay Summary of Outcomes
A new eye drop-activated gene therapy could replace repeated eye injections for patients with diabetic eye disease, offering a safer, less invasive, and more precise treatment to prevent vision loss.
Key results
The study first confirmed that topically administered small-molecule eye drops were able to penetrate the ocular barriers and accumulate within retinal tissue, as validated by HPLC- mass spectrometry. In the proliferative retinopathy model (Kimba), the tunable anti-VEGF gene therapy demonstrated a moderate benefit in preventing retinal vascular leakage and significantly reduced the density of abnormal retinal vessels following topical eye drop administration, both of which are hallmark features of diabetic retinopathy. To further evaluate therapeutic efficacy under diabetic conditions, the 9-month-old Akita mouse model was employed. In this model, the tunable anti-VEGF gene therapy provided significant protection against retinal degeneration induced by diabetic insult. Importantly, our data also demonstrate that the tunable anti-VEGF gene therapy did not adversely impact retinal or vascular structure, as evaluated by in vivo retinal imaging.
Implications for Clinical Practice/Science and Future Research
This study establishes proof of concept for a tunable, non-invasive method for controlling gene therapy in the retina, opening new avenues for precision-controlled gene therapies beyond anti-VEGF applications. The next steps include optimising the dosing regimen and duration of therapeutic effect, evaluating the long-term safety and efficacy of repeat activation cycles, validating the platform in larger preclinical animal models, and progressing toward supporting future clinical translation.
This research project was funded by AVR in 2024